OrthoPediatrics Corp. (KIDS) Stock Price & Analysis

OrthoPediatrics Corp. (KIDS) closed at USD 30.8 on Wednesday, October 28, 2026, up 29.30% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 23.82; the Oct 28, 2026 session ranged USD 24.79–31.51 on volume of 1,793,736 shares. Market capitalization is $804.18M, with a 52-week range of USD 14.42–31.51 (NGM). Source: Nexqual, retrieved October 28, 2026 at 22:57 UTC.

Also available as compact Markdown for AI agents: nexqual.com/KIDS.md

Key facts (KIDS)

• Last four reported quarters (through Sep 30, 2026): revenue $264M, net income -$33.9M (-12.8% margin), free cash flow $3.2M (SEC filings).
• Insider open-market sales, last ~7 months: 12 Form 4 filings, $46.7M; 12 not under a Rule 10b5-1 plan ($46.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 30.25 (range 27–35).
• Total return with dividends: 1Y +87.1% vs S&P 500 +13.6%; 5Y -56.7% vs S&P 500 +79.8%.
• Next earnings: 2026-10-27, EPS estimate USD -0.19, revenue estimate $69.1M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (KIDS)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (KIDS)

P/S 3.0x · EV/Sales 3.3x · P/FCF 252.9x · P/B 2.4x · FCF yield 0.40% · Earnings yield -4.21% · Net debt $60.4M · EV $865M

Insider sales (SEC Form 4, open-market, last ~7 months) (KIDS)

0 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (KIDS)

Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 30.25 (low 27, high 35).

Rating changes, last 120 days:

Total return (dividends reinvested) (KIDS)

KIDS earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

KIDS recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

KIDS suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 4, 2026.

KIDS analyst estimates and revisions

KIDS options: expected move

30-day implied volatility 45.8% vs 83.6% realized over the last 30 trading days. Put/call ratio (volume) 0.02. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 22:57 UTC)

Technical Analysis (KIDS)

Nexqual's technical model rates KIDS "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 28, 2026 at 22:57 UTC.

Analyst Ratings (KIDS)

Wall Street analysts rate KIDS "Buy" based on 7 analysts, with a mean price target of USD 30.25 (range USD 27–35), per Nexqual as of October 28, 2026 at 22:57 UTC.

Earnings (KIDS)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 22:57 UTC.

Financials & Fundamentals (KIDS)

Source: Nexqual, October 28, 2026 at 22:57 UTC.

Financial Health Score (KIDS)

Nexqual rates OrthoPediatrics Corp.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 22:57 UTC.

Ownership (KIDS)

Source: Nexqual, October 28, 2026 at 22:57 UTC.

Leadership (KIDS)

OrthoPediatrics Corp. is led by David R. Bailey, President, CEO & Director, per Nexqual as of October 28, 2026 at 22:57 UTC.

Major Backers & Investors (KIDS)

Notable institutional backers of OrthoPediatrics Corp. include Brown Advisory Inc., Braidwell LP , Granahan Investment Management LLC, according to Nexqual as of October 28, 2026 at 22:57 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 22:57 UTC.

From OrthoPediatrics Corp.'s Latest SEC 10-K Filing (filed 2026-03-04)

Key Strengths & Strategy (as disclosed to the SEC)

• In 2022, we acquired MD Ortho, a manufacturer of orthopedic clubfoot products, and Pega Medical, a medical device company which sells a portfolio of trauma and deformity correction devices for children, including the Fassier-Duval Telescopic Intramedullary System designed to treat osteogenesis imperfecta.
• We estimate that the portion of this market that we currently serve represents a $6.2 billion opportunity globally, including over $2.8 billion in the United States.
• We currently serve a portion of the pediatric orthopedic implant market that we estimate represents a $6.2 billion opportunity globally, including over $2.8 billion in the United States.
• Our global revenue from this category for the year ended December 31, 2025 was $166.3 million, an increase of 15% over the prior year, and represented 70% of total revenue.

Partnerships

• Beyond working with them to develop innovative products, we intend to deepen our partnership with surgeons by leveraging the experience of our senior management team, including our Medical Director, to expand our clinical education programs and partnerships with teaching hospitals, sponsor surgical workshops for residents and fellows and support worthwhile clinical research projects.
• Our broad product offering has made us, within the three categories of the market that we currently serve, the only provider of comprehensive solutions to pediatric orthopedic surgeons, who for the most part are generalists performing a wide range of orthopedic surgeries. • Partnership with Pediatric Orthopedic Surgeons and Pediatric Surgical Societies.

Legal & Regulatory Risks (Item 1A, quoted)

• Our products and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements, including but not limited to the HDE requirements and MDD/MDR regulations, could harm our business.
• We may not receive the necessary clearances or approvals for our future products, and failure to timely obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.
• Any modification to a 510(k)-cleared product that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA.
• Our products must be manufactured in accordance with federal and state regulations, and we could be forced to recall our installed systems or terminate production if we fail to comply with these regulations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 22:57 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt